That kind of international collaboration will be a lot harder if we have multiple payers and health technology assessment bodies. I think it adds to the argument for a national decision-maker so that we can collaborate. You're seeing this already to some extent when a few European countries recently decided to join up to make decisions around rare diseases therapies for a whole bunch of reasons, such as improved bargaining power and to collaborate.
I think that makes the case for national pharmacare here, as well.